These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16156424)

  • 1. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education.
    Hackett GI
    Clin Cornerstone; 2005; 7(1):57-65. PubMed ID: 16156424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How new drugs help treat erectile dysfunction.
    Weeks B; Ficorelli CT
    Nursing; 2006 Jan; 36(1):18-9. PubMed ID: 16394991
    [No Abstract]   [Full Text] [Related]  

  • 5. Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
    Fusco F; Sicuteri R; Rossi A; Kontodimas S; Haro JM; Imbimbo C; Mirone V;
    Asian J Androl; 2009 Sep; 11(5):629-37. PubMed ID: 19701217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical monograph for drug formulary review: erectile dysfunction agents.
    Campbell HE
    J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of ED: PDE-5 Inhibitors.
    Shabsigh R
    Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
    Shindel AW
    J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient education series. Erectile dysfunction.
    Lewis JH; Rosen R; Goldstein I
    Nursing; 2005 Feb; 35(2):64. PubMed ID: 15706284
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
    Scranton RE; Goldstein I; Stecher VJ
    J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
    McCullough A
    Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.